Teva Pharmaceutical Industries Ltd.

Regulatory Filings • Mar 8, 2025

FORM 4			OMB APPROVAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. (Print or Type Responses)	OMB Number: 3235-0287 Estimated average burden hours per response
1. Name and Address of Reporting Person * Daniell Richard		2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ]	5. Relationship of Reporting Person(s) to Issuer	(Check all applicable)
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,		3. Date of Earliest Transaction (Month/Day/Year) 03/05/2025	_ Director X __ Officer (give title below)	_ 10% Owner ___ Other (specify below) Exec. VP, European Commercial
(Street)		4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person
Tel Aviv, L3 6944020			___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month /Day/Year)	2A. Deemed Execution Date, if any	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
		(Month/Day /Year)

Ordinary Shares (1) 03/05/2025 M 22,576 A (2) 119,345 D

Ordinary Shares (1) 03/05/2025 S

Ordinary Shares (1) 03/05/2025 S

(City)	(State)	(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
		2. Transaction Date (Month	2A. Deemed Execution	3. Transaction Code	4. Securities Acquired (A) or Disposed of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)

Code V Amount

(A) or

(D) Price

(3) 22,576 D \$ 15.9139 (4) 96,769 D

(3) 48,385 D \$ 15.901 (5) 48,384 D

1. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

2. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month /Day/Year)	3A. Deemed Execution Date, if any (Month/Day /Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities	10. Ownership Form of Derivative	11. Nature of Indirect Beneficial Ownership
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Beneficially Owned Following Reported Transaction (s) (Instr. 4)	Security: Direct (D) or Indirect (I) (Instr. 4)	(Instr. 4)
Restricted Share Units	(2)	03/05/2025		M			22,576	(6)	(6)	Ordinary Shares (1)	22,576	\$ 0	0	D
Restricted Share Units	(2)	03/05/2025		A		69,182		(7)	(7)	Ordinary Shares (1)	69,182	\$ 0	69,182	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

• 2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
• 3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024.
• 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.795 to \$16.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
• 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.9 to \$15.905, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
• 6. Restricted share units were granted on March 5, 2021, with 22,576 vested on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025.
• 7. Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029.

/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 03/07/2025

Signature of Reporting Person ** Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.